TORONTO, ON (April 25, 2013) – Dr. Nicole Onetto, Deputy Director and Chief Scientific Officer of the Ontario Institute for Cancer Research (OICR), today announced that OICR has been selected by the Canadian Partnership Against Cancer (CPAC) to develop the coordinating centre for the Canadian Cancer Clinical Trials Network (CCCTN). Dr. Janet Dancey, OICR’s Director of the High Impact Clinical Trials Program, will be the Scientific Director and lead the CCCTN coordinating centre. The collaborating organizations are the NCIC Clinical Trials Group and N2 (Network of Networks).
TORONTO, ON (April 25, 2013) – The Ontario Institute for Cancer Research (OICR) and the Ontario Genomics Institute (OGI) today announced that Dr. Lincoln Stein, OICR’s Program Leader, Informatics and Bio-computing, has been awarded $250,000 through Genome Canada’s Bioinformatics and Computational Biology competition, in partnership with the Canadian Institutes of Health Research (CIHR). Dr. Stein and his colleague Dr.
TORONTO, ON (April 22, 2013) — Dr. Tom Hudson, President and Scientific Director of the Ontario Institute for Cancer Research (OICR) today announced a collaboration with Janssen Inc. to find and test new biomarkers to identify patients with hormone resistant prostate cancer at high risk for disease progression and biomarkers of response to therapy. These biomarkers could lead to more personalized treatments and fewer side effects for prostate cancer patients.
Toronto, Dec. 18, 2012 – Dr. Tom Hudson, President and Scientific Director of the Ontario Institute for Cancer Research (OICR), today announced that scientists at the Institute have developed a new computer-based method to identify gene signatures that can serve as prognostic biomarkers for cancer. The researchers, Drs. Guanming Wu, Research Associate, and Lincoln Stein, Platform Leader and Principal Investigator, Informatics and Bio-computing Platform, used this technique to discover gene expression signatures related to survival in breast and ovarian cancers.
Toronto – December 4, 2012. The International Cancer Genome Consortium (ICGC) today announced four new projects in China to identify the genomic drivers in colorectal, esophageal, liver and nasopharyngeal cancers, helping lay the foundation for developing treatments tailored to patients’ individual needs. China is a founding member of the ICGC, having launched a gastric cancer project in 2008.
TORONTO, ON (November 13, 2012) — The Ontario Institute for Cancer Research (OICR) and MaRS Innovation (MI) today announced $1.5 million in funding from OICR over three years to further develop Cellax™, a nanoparticle drug that could offer an alternative to chemotherapy with fewer side effects.
“Cellax is promising because it provides a more targeted strategy for treating tumours, killing tumour cells while minimizing the effect on healthy tissue,” said Dr. Rima Al-awar, Director, OICR’s Medicinal Chemistry Platform.
Toronto, Sept. 3, 2012 - New research published today in the Journal of
Experimental Medicine may provide a new avenue for the treatment of Acute Myeloid
Leukemia (AML) and a solution to the high rate of disease relapse experienced by
patients. The study identified a protein interaction that limits the immune response
to AML and provides a method to disrupt it.
The study was led by Drs. Jean Wang, Affiliate Scientist at the Ontario Cancer
Institute (OCI), the research arm of the University Health Network’s Princess
Toronto, Ontario – June 7, 2012. The Ontario Institute for Cancer Research (OICR) today announced $1.5 million in funding over three years for the development of a new drug by Toronto-based Fluorinov Pharma, Inc. The drug, called FV-162, is a highly potent, orally-delivered small molecule proteasome inhibitor with significant advantages over drugs currently used to treat multiple myeloma and some forms of Non-Hodgkin’s lymphoma.